A phase II exploratory, multicentre, open-label, non-comparative study of ZD1839 (IressaTM) and radiotherapy in the treatment of patients with glioblastoma multiforme.
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2011
At a glance
- Drugs Gefitinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 12 May 2009 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
- 01 Sep 2006 Status change
- 01 Sep 2006 The expected completion date for this trial is now 1 May 2006.